Search Results

1 - 10 of 1,068 items :

  • "breast cancer" x
Clear All
Etiopathogenic Correlations in Breast Cancer

References 1. Peto R. Mortality from breast cancer in UK has decreased suddenly. Bmj. 1998 Aug 15;317(7156):476-7 2. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000 May 20;355(9217):1822 3. Rouanet G., Gardi S., Larra F.: Le cancer du sein ches de Cammes âgccs de moins de 35 ans. Rev. fr. Gynecol obstet 1993 Feb;88(2):89-90. 4. Sondik EJ. Breast cancer trends. Incidence, mortality, and survival. Cancer. 1994 Aug 1;74(3 Suppl):995-9. 5. Foekens JA

Open access
Breast Cancer in Art Painting

References Baljet, B. 2000. The painted Amsterdam anatomy lessons: anatomy performances in dissecting rooms? Ann. Anat. 182: 3-11. Batistatou, A., Charalabopoulos, K. A. 2005. The art of science: Transitional cell carcinoma of the bladder and Golconda. Med. Hypotheses 65: 970-971. Baum, M. 2003. La Fornarina: breast cancer or not? Lancet 361: 1129. Belkin, K. L., Healy, F. Martin, G. 2004. Painting and sculpture. In: K. L. Belkin, F. Healy (eds), A house of

Open access
Incidence and location of bone metastases in breast cancer

(4),302. 5. McPherson K, Steel C, Dixon JM. ABC of breast diseases: breast cancer—epidemiology, risk factors, and genetics. BMJ: British Medical Journal. 2000; 321(7261),624. 6. Abrams HL. Skeletal metastases in carcinoma. Radiology. 1950; 55:534–538,3. 7. Rivkees A, Crawford J. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAm Med Assoc. 1988; 259:2123-5. 8. Saarto T et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by c1

Open access
Effect of Breast Cancer on Physical Activity in Women

mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 36(5), E359-E386. DOI: 10.1002/ijc.29210. 4. Kruk J. (2006). Fruit and vegetable consumption and the risk of breast cancer. Contemporary Oncology 10(5), 224-230. [in Polish] 5. Tyczyński J.E. (2003). Environmental risk factors for cancer and prevention opportunities (primary prevention). In A. Kułakowski, A. Skowrońska-Gardas (eds), Oncology. Handbook for medical students (pp. 21-27). Warszawa: PZWL. [in Polish] 6. Abdulkareem I.H. (2013

Open access
Pericardial disease after breast cancer radiotherapy

Introduction Nowadays, breast cancer is a highly curable disease. Thanks to the modern oncological treatments, patients with early breast cancer live many years, decades after the treatment. For many of them life expectancy some years post treatment is the same as for the general population. 1 Consequences of the oncological treatment may have a very important influence on the quality of the subsequent life. Therefore, all the efforts must be oriented towards treatment benefits as well as in minimizing treatment’s side effects. Radiation therapy is an

Open access
Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer

References 1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82. 2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. 3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab

Open access
Male Breast Cancer – Actuality of Our Days

References 1. van Geel AN, van Slooten EA, Mavrunac M & Hart AA. (1985). A retrospective study of male breast cancer in Holland . Br J Surg. 72, 724-727. 2. Silverberg E & Lubero J. (1987): Cancer Statistics. CA. 37,2-19. 3. Haagensen CD. (1985). Diseases of the Breast (ed 3). Philadelphia: WB Saunders. 4. Ajayi DO, Oseghe DN & Ademiluyi SA. (1982). Carcinoma of the male breast in West Africans and a review of world literature. Cancer. 50,1664-1667. 5. Nirmul D, Pegoraro, RJ, Naidoo C & Joubert SM. (1983). The sex hormone profile of male

Open access
Breast Cancer - Clinical Implication

America 2004; 42 : 821-30. Jacobs TW, Conolly JL, Schnitt SJ. Non malignant leisions in breast core needle biopsie: to excise or not excise? AM J Surg Pathol 2002; 26 : 185-197. Silva OE, Zurrida S. Breast Cancer: A Practical Guide. Elsevier 2000; 11-87. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B

Open access
Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer

Introduction The advent of trastuzumab, a humanized monoclonal antibody against the extracellular domain of human epidermal growth factor receptor-2 (HER2), represented a major breakthrough in the treatment of patients with HER2-positive breast cancer. Long term follow-up from the initial large adjuvant trials with trastuzumab continue to show some remarkably positive results. 1 The current standard adjuvant systemic treatment of early HER2-positive breast cancer consists of chemotherapy (CT) plus 12 months of trastuzumab, with or without endocrine

Open access
Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity

-31. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18 : 243-59. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23 : 2597-605. Velenik V, Oblak I, Kodre V. Managing anemia with epoetin alfa in patients with rectal cancer. Radiol Oncol 2005; 39 : 133-40. Henke M

Open access